Please login to the form below

Not currently logged in
Email:
Password:

Phytopharm

This page shows the latest Phytopharm news and features for those working in and with pharma, biotech and healthcare.

Phytopharm shares dive as Parkinson's drug fails

Phytopharm shares dive as Parkinson's drug fails

Phytopharm's chief executive Tim Sharpington said the company would not be spending any more on R&D while the strategic review is taking place. ... The latest disappointment comes after Phytopharm switched its initial focus on complex plant

Latest news

  • Still afloat

    Some cash-strapped but entrepreneurial examples include Cambridgeshire-based Phytopharm, whose novel molecule for Parkinson's and Alzheimer's has reversed the loss of dopaminergic neurones (restoring learning and memory ability)

  • Pharma news in brief

    Cash blow for Phytopharm. Phytopharm, which specialises in developing medicines from plants, reassured investors that finances were still strong, following the abrupt end to a £24m fund raising deal. ... However, Richard Dixey, Phytopharm's chief

  • Pharma news in brief

    Plant product firm reaches milestone. Biotech company Phytopharm, which specialises in generating medical products from plant extracts, has achieved its first interim profit as milestone payments from licensing partners rolled in. ... Phytopharm was also

  • R&D news in brief

    Phytopharm plans fundraising. Biopharmaceutical company Phytopharm, is planning to raise £23.9m through a UK placing, US private placing and open offer of 13.3m new shares. ... Phytopharm secured a licensing deal with Unilever in December 2004 for the

  • Pharma news in brief

    Phytopharm seeks bargaining funds. Phytopharm, a pharmaceutical plant-product research company, is seeking to raise £23.9m to strengthen its negotiating position with licensing partners.

More from news
Approximately 1 fully matching, plus 24 partially matching documents found.

Latest Intelligence

  • Pharma deals during February 2013 Pharma deals during February 2013

    Another failure this month has been Phytopharm's phase II compound, Cogane, in early stage Parkinson's disease. As Phytopharm does not have a portfolio of other late stage projects to

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Oncosec

OncoSec is a clinical-stage biotechnology company focused on developing cytokine-based intratumoral immunotherapies to stimulate the body's immune system to target...

Latest intelligence

Article: Like, Like, Like: Harnessing the power of social media insights
...
Its Know Your Numbers week
Do you know yours?...
What is changing in mental health and dementia care?
Paul Midgley, of Wilmington Healthcare, takes a look at the NHS Long Term Plan's bid to transform mental health and dementia services...

Infographics